PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

Logo of bmccancBioMed Centralsearchsubmit a manuscriptregisterthis articleBMC Cancer
 
From:
Published online 2008 March 28. doi: 10.1186/1471-2407-8-82

Table 3

Characteristics of 4 randomized trials comparing gemcitabine to gemcitabine plus other cytotoxic agents

ReferenceYearnTreatment regimenStage IV (%)Male (%)PS 0–1 (%)
Oettle2005282Gem 1000 mg/m2 for 3 of 4 wks925488
283Gem 1250 mg/m2 d1, 8 + Pemetrexed 500 mg/m2 d8 q 3 wks906085
Rocha Lima2004180Gem 1000 mg/m2 for 7 of 8 wks, then wkly for 3 of 4 wks815374
180Gem 1000 mg/m2 + Irinotecan 100 mg/m2 d1+8 q 3 wks825778
Stathopoulos200670Gem 900 mg/m2 for 3 of 4 wks866086
60Gem 900 mg/m2 d1, 8 + Irinotecan 300 mg/m2 d8, q 4 wks786587
O'Reilly2004174Gem 1000 mg/m2 for 7 of 8 wks, then wkly for 3 of 4 wks785752*
175Gem 1000 mg/m2 d1, 8 + Exatecan 2 mg/m2 d1+8 q 3 wks795351*

* KPS = 90–100%; PS = performance status;